The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 151-156

  Koprich, James B ^a,b   Huot, Philippe ^a   Fox, Susan H ^a,c   Jarvie, Keith ^d,e   Lang, Anthony E ^a,c   Seeman, Philip ^d   Brotchie, Jonathan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Atuka Inc   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d Clera Inc   (Canada)

^e Ontario Ministry of Economic Development and Trade   (Canada)

Author keywords

Antipsychotic; Dyskinesia; L DOPA; Non human primate; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CHLORPROMAZINE; CLOZAPINE; CLR 151; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; PLACEBO; QUETIAPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DYSKINESIA; FEMALE; HUMAN; MACACA; MALE; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; RISK REDUCTION; VISUAL HALLUCINATION;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BUTYROPHENONES; CLONING, MOLECULAR; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; MPTP POISONING; PARKINSON DISEASE, SECONDARY; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2;

EID: 84872593200     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.008     Document Type: Article

References (38)

1. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005, 20(8):932-936.
2. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999, 290(3):1034-1040.
3. Bonsi P., Cuomo D., Picconi B., Sciamanna G., Tscherter A., Tolu M., et al. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 2007, 32(2):189-195.
4. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005, 20(8):919-931.
5. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994, 5(18):2586-2588.
6. Fahn S. Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl 2006, (71):1-15.
7. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., Brotchie J.M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001, 16(4):642-650.
8. Fox S.H., Lang A.E., Brotchie J.M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord 2006, 21(10):1578-1594.
9. Fox S.H., Visanji N.P., Johnston T.H., Gomez-Ramirez J., Voon V., Brotchie J.M. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 2006, 63(9):1343-1344.
10. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7(10):927-938.
11. Fox S.H., Chuang R., Brotchie J.M. Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res 2008, 172:479-494.
12. Fox S.H., Visanji N., Reyes G., Huot P., Gomez-Ramirez J., Johnston T., et al. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 2010, 37(1):86-95.
13. Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005, 20(5):523-539.
14. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22(2):179-186.
15. Gottwald M.D., Aminoff M.J. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011, 69(6):919-927.
16. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48(4):503-516.
17. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15years. Mov Disord 2005, 20(2):190-199.
18. Jackson M.J., Andree T.H., Hansard M., Hoffman D.C., Hurtt M.R., Kehne J.H., et al. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. J Neural Transm 2010, 117(1):55-67.
19. Johnston T.H., Fox S.H., McIldowie M.J., Piggott M.J., Brotchie J.M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010, 333(3):865-873.
20. Kapur S., Seeman P. Atypical antipsychotics, cortical D(2) receptors and sensitivity to endogenous dopamine. Br J Psychiatry 2002, 180:465-466.
21. Koprich J.B., Fox S.H., Johnston T.H., Goodman A., Le Bourdonnec B., Dolle R.E., et al. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov Disord 2011, 26(7):1225-1233.
22. Kurtz A.L., Kaufer D.I. Dementia in Parkinson's disease. Curr Treat Options Neurol 2011, 13(3):242-254.
23. Lea P.M.T., Faden A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 2006, 12(2):149-166.
24. McKean A., Monasterio E. Off-label use of atypical antipsychotics: cause for concern?. CNS Drugs 2012, 26(5):383-390.
25. Morgante L., Epifanio A., Spina E., Zappia M., Di Rosa A.E., Marconi R., et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004, 27(4):153-156.
26. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995, 10(6):731-740.
27. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006, 21(11):1844-1850.
28. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002, 47(1):27-38.
29. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10(4):515-531.
30. Seeman P. 2010 Publication date Jan. 7, 2010. Substituted butyrophenone derivatives. USA.
31. Seeman P., Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999, 156(6):876-884.
32. Tayarani-Binazir K., Jackson M.J., Rose S., McCreary A.C., Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp Neurol 2010, 226(2):320-327.
33. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75(1):141-143.
34. Tresadern G., Bartolome J.M., Macdonald G.J., Langlois X. Molecular properties affecting fast dissociation from the D2 receptor. Bioorg Med Chem 2011, 19(7):2231-2241.
35. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 2005, 19(9):1140-1142.
36. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50(5):1323-1326.
37. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006, 21(11):1879-1891.
38. Zesiewicz T.A., Sullivan K.L., Hauser R.A. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep 2007, 7(4):302-310.